Last updated: August 25, 2026
Aztreonam is a mature, low-growth antibiotic with two economically distinct markets: generic intravenous aztreonam and Gilead’s branded inhaled product Cayston. Injectable aztreonam has lost primary patent protection and competes mainly on hospital contracts, supply reliability, and clinical positioning in patients with serious beta-lactam allergies. Cayston retains a narrower commercial niche in cystic fibrosis, where recurring treatment cycles and limited alternatives support higher pricing.
The molecule’s commercial outlook is stable to declining for standalone products. The principal growth opportunity is aztreonam-avibactam, a combination designed to address serious infections caused by metallo-beta-lactamase-producing Gram-negative bacteria. That product competes in a different, hospital-reserve market and should not be valued as a simple extension of generic aztreonam.
What products contain aztreonam and who markets them?
Aztreonam is a synthetic monobactam beta-lactam antibiotic. Its commercial products fall into three groups.
| Product |
Active ingredient |
Dosage form |
Primary use |
Commercial position |
| Azactam and generic equivalents |
Aztreonam |
Intravenous or intramuscular injection |
Serious susceptible Gram-negative infections |
Mature generic hospital product |
| Cayston |
Aztreonam lysine |
Inhalation solution delivered through an Altera nebulizer |
Chronic pulmonary infection caused by Pseudomonas aeruginosa in cystic fibrosis |
Branded specialty product |
| Aztreonam-avibactam products |
Aztreonam plus avibactam |
Intravenous combination |
Complicated infections caused by resistant Gram-negative organisms |
Newer anti-infective segment |
The U.S. Food and Drug Administration approved Azactam in 1986. The original product was developed and commercialized by E.R. Squibb, now part of Bristol Myers Squibb. The injectable product later became available from multiple generic manufacturers.
FDA approved Cayston in 2010 for improvement of respiratory symptoms in cystic fibrosis patients with P. aeruginosa. The product is administered as 75 mg three times daily for 28 days, generally followed by 28 days off treatment. The treatment-cycle design creates recurring demand but limits annual exposure per patient relative to continuous therapies. [1]
How large is the aztreonam market?
The total aztreonam market is fragmented and is not reported as a single public market category. Generic injectable sales are distributed across manufacturers and hospital channels, while Cayston sales are included in Gilead’s product reporting.
The commercial value is divided as follows:
- Generic injectable aztreonam generates volume but limited unit economics.
- Cayston generates higher revenue per treated patient because it is a branded, device-dependent specialty product.
- Aztreonam-avibactam has the potential to create a new premium segment, subject to regulatory approval, formulary adoption, and demonstrated clinical utility.
Generic injectable aztreonam is primarily purchased through hospitals, group purchasing organizations, wholesalers, and integrated health systems. Demand is relatively inelastic during shortages or when clinicians need a monobactam option for patients with severe immediate hypersensitivity to penicillins or cephalosporins.
Cayston is distributed through specialty pharmacy and specialty pulmonary-care channels. Its commercial base is concentrated in cystic fibrosis treatment centers and patients who require inhaled anti-pseudomonal therapy.
What is the financial trajectory for injectable aztreonam?
Injectable aztreonam has the financial profile of a mature generic antibiotic rather than an innovative branded medicine.
Revenue drivers
Revenue depends on:
- Hospital utilization for serious Gram-negative infections.
- Use in patients with documented or presumed beta-lactam allergy.
- Availability of alternative agents, including fluoroquinolones, aminoglycosides, ceftazidime, cefiderocol, and newer beta-lactam/beta-lactamase inhibitor combinations.
- Generic supply continuity.
- Contract pricing and wholesaler inventory.
- Temporary shortages affecting competing antibiotics.
The product has a clinically differentiated allergy profile. Aztreonam generally has low cross-reactivity with penicillins and most cephalosporins, although caution is required with ceftazidime because of an identical side chain. That positioning supports demand in selected hospital patients, but it does not create broad pricing power.
Margin and pricing profile
The core injectable product faces several forms of financial pressure:
- Multiple generic suppliers reduce average selling prices.
- Hospital contracts reward low cost and reliable delivery.
- Injectable antibiotics have manufacturing, sterility, and quality-control costs that limit the number of viable suppliers.
- Shortage events can produce temporary price increases but do not establish durable pricing power.
- Newer resistant-pathogen therapies can displace aztreonam in severe infections where susceptibility or resistance patterns favor newer agents.
The result is a low-growth market with episodic revenue volatility. A manufacturer can improve performance through supply reliability, shortage participation, or institutional contracts, but sustained expansion generally requires a differentiated formulation or combination product.
What is the financial trajectory for Cayston?
Cayston has a stronger revenue profile than generic injectable aztreonam because it is a branded specialty product with a defined patient population and a proprietary delivery system.
Its main commercial advantages are:
- Recurring 28-day treatment cycles.
- Specialized cystic fibrosis prescribing.
- Limited direct substitution for patients who respond to or require inhaled aztreonam.
- Integration into chronic pulmonary infection management.
- Distribution through specialty channels with greater manufacturer control.
Its limitations are significant:
- The cystic fibrosis population is relatively small.
- Patients may rotate among inhaled antibiotics such as tobramycin, aztreonam, and colistimethate.
- The product requires the Altera nebulizer system.
- Reimbursement and prior authorization can restrict use.
- The product does not treat the broader hospital infection market.
- Cystic fibrosis treatment is shifting toward highly effective CFTR modulator therapy, which can reduce pulmonary disease burden and affect demand for chronic anti-infective products over time.
Gilead does not generally present Cayston as a standalone high-growth franchise in the way it reports major HIV, oncology, or liver products. Its financial role is that of a specialty, mature product with defensible but limited revenue exposure. Exact global Cayston revenue should be taken from Gilead’s product-level disclosures for the relevant fiscal year rather than inferred from broader anti-infective market estimates. [2]
When did aztreonam lose patent exclusivity?
The original injectable aztreonam patent estate is expired. The product has been commercially available for decades, and generic versions are established in the United States and other major markets.
| Protection category |
Status |
| Original composition and injectable product protection |
Expired |
| Generic injectable competition |
Established |
| Original Azactam brand protection |
Commercially obsolete as a market-exclusivity tool |
| Cayston regulatory exclusivity |
Expired |
| Cayston formulation and device-related protection |
Historically relevant, but not equivalent to broad molecule exclusivity |
| Aztreonam-avibactam protection |
Combination-specific and dependent on the individual product’s regulatory and patent estate |
The principal commercial barrier for injectable aztreonam is now manufacturing and regulatory execution, not basic molecule ownership. Sterile injectable production requires validated processes, approved facilities, quality systems, and reliable active pharmaceutical ingredient supply. Those requirements can limit the number of active competitors even when the product has no meaningful molecule patent barrier.
What is the Orange Book status of aztreonam?
The Orange Book treatment differs by product.
Injectable aztreonam
Generic injectable aztreonam products rely on abbreviated new drug applications and compete against the historical reference product. The relevant market is characterized by generic approvals, hospital procurement, and manufacturing capacity rather than active primary patents.
Cayston
Cayston’s Orange Book position is more complex because the product combines:
- Aztreonam lysine as the active ingredient.
- A specific inhalation formulation.
- A dedicated nebulizer system.
- A cystic fibrosis method of use.
Any follow-on product must address pharmaceutical equivalence, bioequivalence or clinical requirements, device compatibility, labeling, and regulatory exclusivity. A generic version of injectable aztreonam would not substitute for Cayston because the dosage form, administration route, formulation, and clinical use differ.
Cayston’s historical exclusivity was tied to its orphan indication. FDA orphan-drug exclusivity generally lasts seven years from approval, subject to statutory conditions. That period has expired for the 2010 approval. [1] Later patents, device claims, formulation claims, or regulatory requirements may still affect follow-on entry, but they do not recreate broad orphan exclusivity.
What formulation patents protect Cayston?
The defensible intellectual-property elements around Cayston are narrower than a composition-of-matter patent on aztreonam. They may include:
- Aztreonam lysine formulations suitable for inhalation.
- Stability and concentration characteristics.
- Nebulizer performance.
- Drug-device combinations.
- Pulmonary delivery methods.
- Cystic fibrosis dosing regimens.
- Manufacturing processes for sterile inhalation products.
These claims have greater commercial relevance than the expired injectable molecule patents. A competitor can possess aztreonam as an active ingredient yet still face development and approval barriers if it cannot replicate the required inhaled formulation, device performance, or clinical labeling.
The patent value is therefore product-specific. It is strongest when claims cover the complete product configuration and weakest when claims cover broad, easily designed-around formulation concepts.
Are there Paragraph IV challenges to aztreonam products?
Paragraph IV risk is materially different for injectable aztreonam and Cayston.
Injectable aztreonam
Paragraph IV litigation is no longer the central market issue because generic injectable versions already exist. New entrants may still challenge listed patents if a particular formulation or product has active Orange Book claims, but the molecule itself is an established generic.
Cayston
A proposed generic or follow-on inhaled aztreonam product could use a Paragraph IV certification against unexpired listed patents. The commercial outcome would depend on:
- The number and scope of listed patents.
- Whether the proposed product uses the same or a different nebulizer.
- FDA’s determination of substitutability.
- The sponsor’s ability to demonstrate comparable pulmonary delivery.
- Patent litigation and any settlement agreement.
- Reimbursement acceptance by cystic fibrosis treatment centers.
A generic Cayston launch would likely be slower and more expensive than a standard injectable generic because the development program must address both drug and device performance.
Which companies compete with aztreonam?
Competition depends on the product and clinical setting.
Hospital injectable competition
Relevant alternatives include:
- Ceftazidime.
- Cefepime.
- Piperacillin-tazobactam.
- Meropenem and other carbapenems.
- Fluoroquinolones.
- Aminoglycosides.
- Cefiderocol.
- Ceftazidime-avibactam.
- Meropenem-vaborbactam.
- Imipenem-cilastatin-relebactam.
Aztreonam has a specific advantage when clinicians need Gram-negative coverage in a patient with a serious allergy concern. It is less competitive when organisms are resistant, when mixed Gram-positive and anaerobic coverage is needed, or when a newer agent has a superior susceptibility profile.
Inhaled pulmonary competition
Cayston competes with inhaled tobramycin products, including nebulized and dry-powder formulations, and inhaled colistimethate. The choice is influenced by prior microbiology, tolerability, treatment history, administration burden, payer policy, and patient preference.
How does aztreonam compare with newer beta-lactam antibiotics?
| Attribute |
Aztreonam |
Newer beta-lactam or beta-lactamase inhibitor |
| Patent position |
Mature or expired for standalone product |
Often active and commercially protected |
| Price |
Low for generic injection |
Often substantially higher |
| Allergy role |
Useful in selected beta-lactam-allergic patients |
Varies by structure and side-chain profile |
| Resistance coverage |
Limited against many contemporary mechanisms |
Often designed for specific resistant organisms |
| Hospital use |
Established, selective |
Targeted to serious resistant infections |
| Formulary role |
Stewardship-sensitive generic |
Reserve or restricted-use product |
| Revenue growth |
Mainly volume and supply events |
New-product launch and premium pricing |
Aztreonam remains relevant because it solves a specific clinical problem at low acquisition cost. Newer products generate more revenue per treatment course but are used in narrower, resistance-driven situations and face payer controls.
What licensing deals affect aztreonam?
Gilead acquired the rights to Cayston through its acquisition of Corus Pharma in 2005. Corus had developed Cayston for cystic fibrosis-related pulmonary infection. The transaction gave Gilead a specialty respiratory product and a cystic fibrosis commercial platform. [3]
Aztreonam-avibactam has involved collaboration and licensing activity outside the traditional generic aztreonam market. The commercial importance of these arrangements is tied to the avibactam component, combination development, and access to resistant Gram-negative hospital markets rather than to the expired aztreonam molecule.
What manufacturing and supply barriers affect aztreonam?
Manufacturing is a more important barrier than molecule patents for the mature injectable product.
Key barriers include:
- Sterile fill-finish capacity.
- Validation of aseptic processes.
- Active pharmaceutical ingredient sourcing.
- Container-closure integrity.
- Batch-release testing.
- Hospital inventory requirements.
- Regulatory inspection performance.
- Low-margin economics that discourage redundant capacity.
For Cayston, the manufacturing challenge is broader. The sponsor must produce a sterile inhalation solution with consistent aerosol performance and maintain the associated nebulizer supply chain. Device manufacturing, software or delivery-system controls where applicable, and patient training add operational complexity.
These barriers can preserve market concentration even after patent expiry. They do not, however, provide the same long-term protection as an enforceable composition patent.
What generic launch scenarios exist for aztreonam?
Injectable aztreonam
The generic launch scenario is already realized. Additional entrants could obtain share through:
- Lower contract pricing.
- Reliable supply during shortages.
- Improved wholesaler coverage.
- Stronger hospital contracting.
- Private-label supply arrangements.
Revenue upside per entrant is limited unless a supplier captures significant institutional volume or benefits from a competitor disruption.
Cayston
A follow-on launch would probably proceed in stages:
- Regulatory filing and patent certification.
- Patent litigation or negotiated settlement.
- Device and formulation validation.
- Limited specialty-pharmacy launch.
- Payer and treatment-center adoption.
- Gradual substitution if clinical and delivery equivalence are accepted.
A successful follow-on could pressure price and reduce Gilead’s net sales. The erosion rate would depend on the number of approved competitors and whether automatic pharmacy substitution is available.
Aztreonam-avibactam
The combination has the highest potential to reset the financial trajectory of the aztreonam franchise. It could command premium pricing if positioned for infections involving metallo-beta-lactamases, where treatment options are limited. Its commercial ceiling depends on resistance prevalence, diagnostic testing, hospital stewardship, formulary restrictions, and clinical evidence against existing rescue regimens.
How strong is the aztreonam patent estate?
The standalone aztreonam patent estate is weak as a source of exclusivity because the original molecule and injectable product are mature generic technologies.
The overall product estate can be ranked as follows:
| Product |
Patent strength |
Main source of defensibility |
| Generic injectable aztreonam |
Low |
Manufacturing, supply, contracts |
| Cayston |
Moderate but narrow |
Inhaled formulation, delivery device, method of use, specialty distribution |
| Aztreonam-avibactam |
Potentially strong |
Combination patents, regulatory exclusivity, clinical differentiation |
The commercial value of Cayston protection is greater than the standalone patent strength suggests because device and clinical-development requirements can delay competition. The value of aztreonam-avibactam protection will depend on approved indications and the breadth of claims covering the combination, dosing, and resistant-pathogen use.
What is the investment outlook for aztreonam?
Aztreonam is unlikely to deliver broad molecule-level revenue growth. The investment case is segmented:
- Generic injectable aztreonam offers defensive hospital demand but limited pricing power.
- Cayston offers mature specialty revenue with concentration risk and potential follow-on competition.
- Aztreonam-avibactam offers the clearest growth opportunity but carries development, regulatory, stewardship, and market-adoption risk.
- Manufacturing assets can create value through supply reliability even when intellectual-property protection is weak.
- Revenue exposure to the standalone molecule is likely modest for diversified pharmaceutical companies.
The most relevant diligence questions are product-specific: current hospital contract share, shortage history, supplier concentration, Cayston patient counts, payer restrictions, listed patents, device dependence, and the clinical positioning of aztreonam-avibactam.
Key Takeaways
- Aztreonam is a mature monobactam antibiotic with separate injectable, inhaled, and combination-product markets.
- Generic injectable aztreonam has no meaningful molecule-level exclusivity and competes on cost and supply.
- Cayston retains a specialized cystic fibrosis market but faces long-term pressure from CFTR modulators and potential inhaled follow-on products.
- The strongest commercial opportunity is aztreonam-avibactam for resistant Gram-negative infections.
- Manufacturing, sterile production, hospital contracting, and device requirements are more important than basic aztreonam patents.
- Public financial reporting does not treat generic aztreonam as a standalone growth franchise; Cayston is a smaller specialty product within Gilead’s portfolio.
- Generic entry risk is high for injectable aztreonam and more technically complex for Cayston.
FAQs
Is aztreonam still under patent?
The original aztreonam molecule and injectable product patents are expired. Product-specific patents may still affect inhaled formulations, devices, or combination products.
Is Cayston the same as intravenous aztreonam?
No. Cayston contains aztreonam lysine and is an inhaled product delivered through a dedicated nebulizer. Intravenous aztreonam is a different dosage form with different regulatory and clinical requirements.
Can aztreonam be used in patients allergic to penicillin?
It may be used in selected patients with serious penicillin allergy concerns, but clinical decisions depend on allergy history, ceftazidime cross-reactivity, organism susceptibility, and the full treatment regimen.
Why is aztreonam-avibactam commercially important?
Avibactam can restore or improve activity against selected resistant Gram-negative bacteria, including organisms producing certain beta-lactamases. The combination targets a premium hospital anti-infective market rather than the low-price generic market.
Does aztreonam have biosimilar risk?
No. Aztreonam is a small-molecule antibiotic, not a biologic. The relevant competitive risks are generic, formulation, device, and combination-product competition.
References
- U.S. Food and Drug Administration. (2010). Cayston (aztreonam lysine) inhalation solution prescribing information.
- Gilead Sciences, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
- Gilead Sciences, Inc. (2005). Gilead Sciences to acquire Corus Pharma.
- U.S. Food and Drug Administration. (1986). Azactam (aztreonam) injection prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Avaliable Orange Book records for aztreonam products.
